GlassScriptPhysician profile
Narissa Seelall
NPI 1255007324
$8,938.46
in general payments reported to CMS, 2019-2025
64 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.71 · 2022: $1,548 · 2023: $2,331 · 2024: $1,698 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,691 · Education: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,690.78 |
| Education | $600.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $616.88 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $528.80 | 2022-2025 | |
| Pfizer INC. | $516.69 | 2022-2025 | |
| Seagen INC. | $485.36 | 2022-2025 | Adcetris, Tivdak, Tukysa |
| Celgene Corporation | $396.19 | 2023-2025 | Reblozyl |
| Janssen Biotech, INC. | $395.61 | 2022-2025 | Erleada, Talvey, Carvykti |
| Astrazeneca Pharmaceuticals LP | $366.92 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Genzyme Corporation | $362.45 | 2022-2025 | |
| Daiichi Sankyo INC. | $331.04 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Eisai INC. | $324.49 | 2021-2025 | |
| Astellas Pharma US INC | $312.80 | 2022-2025 | Vyloy, Padcev |
| Lilly USA, LLC | $288.99 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $221.50 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $215.03 | 2021-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $187.66 | 2021-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $187.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $175.06 | 2022-2025 | Libtayo |
| Incyte Corporation | $171.60 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Beigene USA, INC. | $158.81 | 2023-2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $152.74 | 2022-2025 | Fruzaqla, Iclusig |
| Tersera Therapeutics LLC | $149.87 | 2022-2025 | Zoladex, Xermelo |
| Ipsen Biopharmaceuticals, INC | $144.60 | 2022-2025 | Somatuline Depot, Onivyde |
| Array Biopharma INC | $137.45 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $130.73 | 2023-2025 | Venclexta, Tecentriq, Polivy |
| Gilead Sciences, INC. | $115.68 | 2022-2025 | Trodelvy |
| Emd Serono, INC. | $115.63 | 2023-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $103.76 | 2021-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $94.07 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $89.02 | 2023-2025 | Orgovyx |
| Amgen INC. | $87.78 | 2022-2023 | Lumakras |
| Abbvie INC. | $83.55 | 2023-2025 | |
| Beone Medicines USA, INC. | $78.38 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $78.10 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $74.60 | 2023-2024 | Ojjaara, Zejula, Shingrix |
| Pharmacyclics LLC, An Abbvie Company | $73.66 | 2022-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $72.86 | 2025 | Opdualag, Opdivo |
| Myovant Sciences INC. | $71.94 | 2022 | |
| Acrotech Biopharma INC. | $71.59 | 2022-2024 | Beleodaq |
| Kyowa Kirin, INC. | $58.86 | 2024-2025 | Poteligeo |
| Cti Biopharma Corp. | $53.73 | 2023 | Vonjo |
| Pharmaessentia USA Corporation | $46.61 | 2025 | Besremi |
| Agios Pharmaceuticals, INC. | $38.83 | 2024-2025 | Pyrukynd |
| Recordati_rare_diseases_inc. | $38.58 | 2025 | Enjaymo |
| Alnylam Pharmaceuticals INC. | $37.79 | 2022-2023 | Givlaari |
| G1 Therapeutics, INC. | $37.00 | 2022 | |
| Global Blood Therapeutics, INC. | $36.88 | 2022 | |
| Pharmacosmos Therapeutics INC. | $36.75 | 2023-2025 | Monoferric |
| Taiho Oncology, INC. | $29.74 | 2023-2024 | |
| Springworks Therapeutics, INC. | $29.74 | 2025 | Ogsiveo |
| Immunocore Limited | $27.72 | 2025 | Kimmtrak |
| Blueprint Medicines Corporation | $26.97 | 2025 | Ayvakit |
| Exelixis INC. | $25.78 | 2025 | Cabometyx |
| Genmab U.S., INC. | $24.67 | 2023 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.85 | 2022 | |
| Geron Corporation | $23.66 | 2025 | Rytelo |
| Nuvation Bio INC. | $20.61 | 2025 | Ibtrozi |
| Macrogenics, INC. | $20.55 | 2022 | |
| Morphosys, US INC. | $20.22 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.88 | 2022 | |
| Ge Healthcare | $19.00 | 2022 | |
| Adc Therapeutics America, INC. | $18.80 | 2024 | |
| Foundation Medicine, INC. | $18.42 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.34 | 2025 | Provenge |
| Puma Biotechnology, INC. | $16.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narissa Seelall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.